Progression of systemic sclerosis-associated ILD (SSc-ILD) and effect of nintedanib in subgroups by monocyte and neutrophil counts
M. Kreuter (Heidelberg, Germany), C. Denton (London, United Kingdom), L. Ho (Seattle, Washington, United States), R. Hoyles (Oxford, United Kingdom), I. Glaspole (Melbourne, Victoria, Australia), T. Suda (Hamamatsu, Japan), C. Miede ( Sulzbach (Taunus), Germany), M. Alves (Ingelheim am Rhein, Germany), T. Maher (Los Angeles, CA, United States)
Source: International Congress 2022 – Hot topics in connective tissue disease-associated interstitial lung disease
   
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Kreuter (Heidelberg, Germany), C. Denton (London, United Kingdom), L. Ho (Seattle, Washington, United States), R. Hoyles (Oxford, United Kingdom), I. Glaspole (Melbourne, Victoria, Australia), T. Suda (Hamamatsu, Japan), C. Miede ( Sulzbach (Taunus), Germany), M. Alves (Ingelheim am Rhein, Germany), T. Maher (Los Angeles, CA, United States). Progression of systemic sclerosis-associated ILD (SSc-ILD) and effect of nintedanib in subgroups by monocyte and neutrophil counts. 1449
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|